Study identifier:D8111R00028
ClinicalTrials.gov identifier:NCT05697705
EudraCT identifier:N/A
CTIS identifier:N/A
Real-world Effectiveness oF the OxfoRd-astrazeneca Covid-19 vaccine as a second bOoster dose in Brazil (REFORCO-BRAZIL)
COVID-19
N/A
No
-
All
188814085
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2023 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Population A For evaluating second booster doses | Other: ChAdOx1 nCOV-19 vaccine (Vaxzeria) Used as 2nd booster, 1st booster, or primary series Other: BNT162b2 (Pfizer) Used as 2nd booster, 1st booster, or primary series. Other: Ad26.COV2.S (Janssen) Used as 2nd booster, 1st booster, or primary series. Other: CoronaVac (Sinovac) Used as 2nd booster, 1st booster, or primary series. |
Population B For evaluating first booster doses | Other: ChAdOx1 nCOV-19 vaccine (Vaxzeria) Used as 2nd booster, 1st booster, or primary series Other: BNT162b2 (Pfizer) Used as 2nd booster, 1st booster, or primary series. Other: Ad26.COV2.S (Janssen) Used as 2nd booster, 1st booster, or primary series. Other: CoronaVac (Sinovac) Used as 2nd booster, 1st booster, or primary series. |